Most Clicked StoriesMore >


Celgene to buy Acetylon, spin out new company

BIO SmartBrief | Dec 05, 2016

Celgene has partially acquired Acetylon Pharmaceuticals, which will spin out histone deacetylase assets into a startup company named Regenacy Pharmaceuticals. Celgene will gain global rights to develop Acetylon's drug candidates citarinostat and ricolinostat for oncology, autoimmune diseases and neurodegenerative indications, while Regenacy will have rights to the drugs for other diseases. BioCentury (12/02) Xconomy (12/05)


MedImmune to form spinout with Abpro for bispecific antibody development

BIO SmartBrief | Nov 30, 2016

AstraZeneca signs collaboration deal with Bicycle for up to $1B-plus

BIO SmartBrief | Dec 02, 2016

AbbVie teams up with Johns Hopkins, Northwestern on cancer R&D

BIO SmartBrief | Dec 06, 2016

Senate advances 21st Century Cures Act

BIO SmartBrief | Dec 06, 2016

Sanofi signs deal with JHL to develop biosimilars

BIO SmartBrief | Dec 06, 2016

Caltech spinoff raises $19.15M for gut-CNS therapies

BIO SmartBrief | Dec 02, 2016

Heptares agrees to purchase G7 for $11.8M

BIO SmartBrief | Dec 01, 2016

Ariad's treatment for rare leukemias receives FDA approval

BIO SmartBrief | Dec 01, 2016

Funding round secures $36M for Seattle biotech

BIO SmartBrief | Dec 05, 2016


Find BIO SmartBrief Issues by Date:



BIO News More >


Nikon -- Latest version

BIO SmartBrief | Dec 07, 2016

Save $200 on the BIO CEO & Investor Conference if you register by Dec. 15!

BIO SmartBrief | Dec 07, 2016

Unifirst

BIO SmartBrief | Dec 06, 2016

Are you looking for top biotech talent? Or looking for a biotech job?

BIO SmartBrief | Dec 06, 2016

BIO business solutions -- Latest

BIO SmartBrief | Dec 05, 2016




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more